• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Orexo

21.00 SEK

0.00 %

Less than 1K followers

ORX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
0.00 %
+13.64 %
-11.58 %
-30.23 %
-9.68 %
+5.63 %
+113.85 %
-46.84 %
-76.65 %

Orexo is a Swedish pharmaceutical company that develops improved medicines based on proprietary formulation technologies and with a focus on meeting major medical needs. In the US market, Orexo commercializes treatments for patients suffering from opioid addiction. Products targeting other therapeutic areas are developed and commercialized worldwide through partners.

Read more
Market cap
780.29M SEK
Turnover
91.6K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
16.7.
2026

Interim report Q2'26

22.10.
2026

Interim report Q3'26

4.2.
2027

Annual report '26

Press release6/9/2026, 6:00 AM

Orexo appoints Raheleh Nassaji as SVP Business Development, strengthening its focus on new partnerships

Orexo
Press release5/19/2026, 9:38 AM

DNB Carnegie Access: Orexo: Promising early-stage data

Orexo
Press release5/19/2026, 6:00 AM

Orexo announces positive outcome from an in-vivo study of OX390

Orexo

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release5/7/2026, 3:00 PM

Report from Orexo AB’s annual general meeting May 7 2026

Orexo
Press release4/29/2026, 6:40 AM

DNB Carnegie Access: Orexo: Better visibility, few near-term catalysts – Q1 review

Orexo
Regulatory press release4/28/2026, 5:00 AM

Orexo Q1 2026 Interim Report

Orexo
Press release4/21/2026, 8:00 AM

Invitation to presentation of Orexo´s Q1 2026 Interim Report

Orexo
Regulatory press release3/31/2026, 3:30 PM

Number of shares and votes in Orexo

Orexo
Press release3/30/2026, 10:00 AM

Notice of Annual General Meeting of Orexo

Orexo
Regulatory press release3/27/2026, 9:00 AM

Orexo publishes Annual Report for 2025

Orexo
Press release3/24/2026, 6:53 PM

DNB Carnegie Access: Orexo: Key takeaways from R&D Day

Orexo
Press release3/24/2026, 6:30 AM

Orexo R&D Day - Building global leadership in amorphous drug delivery

Orexo
Press release3/6/2026, 9:00 AM

Invitation & Agenda: Orexo R&D Day on March 24

Orexo
Press release3/6/2026, 8:43 AM

DNB Carnegie Access: Orexo: Management changes no major surprise

Orexo
Press release3/6/2026, 7:00 AM

Orexo changes the organizational structure and management team to increase focus on development of new products

Orexo
Press release3/4/2026, 7:00 AM

Orexo calls for early redemption of its outstanding senior secured social bonds 2024/2028

Orexo
Regulatory press release2/19/2026, 4:30 PM

Orexo: Conversion of Class C shares into ordinary shares and conveyance of ordinary shares within the framework of long-term performance-based incentive programs

Orexo
Press release2/6/2026, 9:53 AM

DNB Carnegie Access: Orexo: Busy quarter paves the way for a fresh start – Q4 review

Orexo
Regulatory press release2/5/2026, 6:00 AM

Orexo Interim Report Q4 2025, incl. Full Year Report

Orexo
Press release2/4/2026, 8:30 AM

Save the date: Orexo to host R&D Day on March 24

Orexo